Protein level of transcription factors AP-1 and NF-κB in selected human gastrointestinal tract tumors;Poziom białka czynników transkrypcyjnych AP-1 i NF-κB w wybranych nowotworach przewodu pokarmowego człowieka

Polski Merkuriusz Lekarski

Volumn 25, Issue 150, 2008, Pages 510-515

  Skrzycki, Michał ^a   Ścibior Bentkowska, Dorota ^a   Podsiad, Małgorzata ^a   Czeczot, Hanna ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

AP 1; Gastrointestinal tract; NF B; Oxidative stress; Tumors

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; FEMALE; GASTROINTESTINAL TUMOR; HUMAN; LIVER TUMOR; MALE; METABOLISM; METASTASIS; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NF-KAPPA B; TRANSCRIPTION FACTOR AP-1; TUMOR MARKERS, BIOLOGICAL;

EID: 58149337313     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Arsura M., Cavin L.G.: Nuclear factor-kB and liver carcinogenesis. Cancer Lett., 2005, 229, 157-169.
2. Ausubel F.M., Brent R., Kingstone R.E. i wsp.: Current Protocols in Molecular Biology. Vol. 2. Wiley J., Massachusets General Hospital, Harvard Medical School, 2000.
3. Bernard D., Quatannens B., Begue A. i wsp.: Antiproliferative and antiapoptotic effects of crel may occur within the same cells via the up-regulation of manganese superoxide dismutase. Cancer Res., 2001, 61(15), 2656-2664.
4. Borrello S., Demple B.: NF-kappa B - independent transcriptional induction of the human manganous superoxide dismutase gene. Arch. Bioch. Biophys., 1997, 348(2), 289-294.
5. Bubici C., Papa S., Pham C.G. i wsp.: The NF-kappa B - mediated control of ROS and JNK signaling. Histol. Histopathol., 2006, 21(1), 69-80.
6. Buchholz T.A., Garg A.K., Chakravarti N. i wsp.: The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin. Cancer Res., 2005, 11(23), 8398-8402.
7. Czeczot H., Skrzycki M., Ścibor D. i wsp.: Aktywnoś ć izoenzymów dysmutazy ponadtlenkowej u chorych z nowotworami przewodu pokarmowego. Adv. Clin. Exp. Med., 2005, 14(4), 731-737.
8. Eliseev R.A., Schwarz E.M., Zuscik M.J. i wsp.: Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NF-kappa B. Exp. Cell Res., 2006, 312(1), 40-50.
9. Fausto N.: Mouse liver tumorigenesis: models, mechanisms, and relevance of human disease. Semin. Liver Dis., 1999, 19, 243-252.
10. Floryk D., Huberman E.: Differentiation of androgen-independent prostate cancer PC-3 cells is associated with increased nuclear factor-kappa B activity. Cancer Res., 2005, 65(24), 11588-11596.
11. Ghosh S., May M.J., Kopp E.B.: NF-kappa B and Rel proteins: evolutionary conserved mediators of immune responses. Annu. Rev. Immunol., 1998, 16, 225-260.
12. Greten F.R., Karin M.: The IKK/NF-kappa B activation pathway - a target for prevention and treatment of cancer. Cancer Lett., 2004, 206(2), 193-199.
13. Jungst C., Cheng B., Gehrke R. i wsp.: Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology, 2004, 39(6), 1663-1672.
14. Kamel I.R., Bluemke D.A.: Imaging valuation of hepatocellular carcinoma. J. Vasc. Intervent. Radiol., 2002, 13, 173-184.
15. Karin M.: The regulation of AP-I activity by mitogen activated protein kinases. J. Biol. Chem., 1995, 270, 16483-16486.
16. Karin M.: How NF-kB is activated: the role of IkB kinase (IKK) complex. Oncogene. (1999), 18: 6867-6874.
17. Koong A.C., Chen E.Y., Mivechi N.F. i wsp.: Hypoxic activation of nuclear factor-kB is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res., 1994, 54, 5273-5279.
18. Korsmeyer S.J., Xiao-Ming Y., Oltvai Z.N. i wsp.: Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family. Bioch. Biophys. Acta, 1995, 1271, 63-66.
19. Kundu J.K., Surh Y.J.: Molecular basis of chemoprevention by resveratrol: NF-kB and AP-1 as potential targets. Mutation Res., 2004, 555, 65-80.
20. Mehic D., Bakiri L., Ghannadan M. i wsp.: Fos and jun proteins are specifically expressed during differentiation of human keratinocytes. J. Invest. Dermatol., 2005, 124(1), 212-220.
21. Nicco C., Laurent A., Chereau C. i wsp.: Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed. Pharmacother., 2005, 59, 169-174.
22. Sen C.K., Packer L.: Antioxidant and redox regulation of gene transcription. FASEB J., 1996, 10(7), 709-720.
23. Shaulian E., Karin M.: AP-1 as a regulator of cell life and death. Nature Cell Biol., 2002, 4, E131-E136.
24. Skrzycki M., Ścibior D., Podsiad M., Czeczot H.: Activity and protein level of CuZnSOD and MnSOD in benign and malignant liver tumors. Clin. Biochem., 2008, 41, 91-96.
25. Takada Y., Mukhopadhyay A., Kundu G.C. i wsp.: Hydrogen peroxide activates NF-kB through tyrosine phosphorylation of IkBα and serine phosphorylation of p65: evidence for the involvement of IkBα kinase and Syk proteintyrosine kinase. J. Biol. Chem., 2003, 278, 24233-24241.
26. Turco M.C., Romano M.F., Petrella A. i wsp.: NF-kappaB/Relmediated regulation of apoptosis in hematologic malignancies and normal hematopoietic progenitors. Leukemia, 2004, 18(1), 11-17.
27. Waris G., Livolsi A., Imbert V. i wsp.: Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J. Biol. Chem., 2003, 278(42), 40778-40787.
28. Zhao Y., Kiningham K.K., Lin S.M., St Clair D.K.: Overexpression of MnSOD protects murine fibrosarcoma cells (FSa-II) from apoptosis and promotes a differentiation program upon treatment with 5-azacytidine: involvement of MAPK and NFkappaB pathways. Antioxid Redox Signal, 2001, 3(3), 375-386.